Teva walloped $163M in hepC ruling, doc 'unfit' for trial

The other shoe has dropped for Teva ($TEVA) and supply chain partners Baxter ($BAX) and McKesson ($MCK) in the case of a hepatitis C outbreak that followed reuse of jumbo-sized vials of propofol at a colonoscopy center. The jury assessed $162.5 million in punitive damages on top of the $20.1 million in compensatory damages it awarded last week to three victims, reports Bloomberg.

Meanwhile, the owner of the Las Vegas colonoscopy center where the procedures took place is unfit to stand trial, his lawyers say, according to the Miami Herald. Gastroenterologist Dipak Desai and two anesthetists from the Desert Shadow Endoscopy Center are accused of infecting 7 patients by reusing endoscopy scopes and jumbo-sized propofol vials--intended for longer-term sedation that that required for a colonoscopy--during outpatient procedures, says the Washington Post.

Last May, in a related case, jurors awarded a victim and his wife $5.1 million in compensatory damages and assessed $500 million in punitive damages against Teva and Baxter.

Teva says it will appeal both the punitive and compensatory damages awards.

Nearly 300 lawsuits stemming from the hepatitis C outbreak are still in the offing.  

- here's the Bloomberg story
- see the Miami Herald coverage
- here's more from the Washington Post

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.